Financials data is unavailable for this security.
View more
Year on year BrightPath Biotherapeutics Co Ltd had revenues fall -98.64% from 5.28m to 72.00k, though the company grew net income from a loss of 1.49bn to a smaller loss of 1.17bn.
Gross margin | 75.00% |
---|---|
Net profit margin | -1,372,495.00% |
Operating margin | -1,365,446.00% |
Return on assets | -80.63% |
---|---|
Return on equity | -102.58% |
Return on investment | -97.29% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at BrightPath Biotherapeutics Co Ltd fell by 473.61m. Cash Flow from Financing totalled 690.96m or 959,665.28% of revenues. In addition the company used 1.16bn for operations while cash used for investing totalled 7.65m.
Cash flow per share | -16.32 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 14.73 |
---|---|
Tangible book value per share | 14.73 |
More ▼
Balance sheet in JPYView more
Current ratio | 4.14 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.2634 |
---|---|
Total debt/total capital | 0.2085 |
More ▼